Markets
Editas Stock Soars 7% After Its Quarterly Loss Narrows And Collaboration Revenue Rises
The gene-editing developer projects cash lasting into the second half of 2028 and has Australian clearance to begin an early-stage trial.
Editas Medicine (EDIT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The gene-editing developer projects cash lasting into the second half of 2028 and has Australian clearance to begin an early-stage trial.
SEC Filings
Partner milestones lifted revenue, while Editas expects its cash to fund operations beyond planned 2027 clinical results.
SEC Filings
The asset manager's passive filing lists 11,937,882 Editas shares and says none were bought to influence control of the gene-editing company.
Earnings
An 8-K says the Strive trial can start in Australia; first safety data are targeted for the first quarter of 2027.